Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2014, Article ID 879497, 9 pages
http://dx.doi.org/10.1155/2014/879497
Research Article

The Feasibility of Using CT-Guided ROI for Semiquantifying Striatal Dopamine Transporter Availability in a Hybrid SPECT/CT System

1Department of Nuclear Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123 Dapi Road, Niaosong District, Kaohsiung City 83301, Taiwan
2Department of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123 Dapi Road, Niaosong District, Kaohsiung City 83301, Taiwan
3Department of Nuclear Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138 Shengli Road, Tainan City 70428, Taiwan

Received 9 June 2014; Revised 22 September 2014; Accepted 23 September 2014; Published 2 November 2014

Academic Editor: Ken Herrmann

Copyright © 2014 Chien-Chin Hsu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Varrone and C. Halldin, “Molecular imaging of the dopamine transporter,” Journal of Nuclear Medicine, vol. 51, no. 9, pp. 1331–1334, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Kägi, K. P. Bhatia, and E. Tolosa, “The role of DAT-SPECT in movement disorders,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 81, no. 1, pp. 5–12, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. J. L. Cummings, C. Henchcliffe, S. Schaier, T. Simuni, A. Waxman, and P. Kemp, “The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration,” Brain, vol. 134, part 11, pp. 3146–3166, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. P. P. Piccini, “Dopamine transporter: basic aspects and neuroimaging,” Movement Disorders, vol. 18, supplement 7, pp. S3–S8, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. H. F. Kung, M.-P. Kung, S.-P. Wey, K.-J. Lin, and T.-C. Yen, “Clinical acceptance of a molecular imaging agent: a long march with [99mTc]TRODAT,” Nuclear Medicine and Biology, vol. 34, no. 7, pp. 787–789, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Darcourt, J. Booij, K. Tatsch et al., “EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 2, pp. 443–450, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. D. S. W. Djang, M. J. R. Janssen, N. Bohnen et al., “SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0,” Journal of Nuclear Medicine, vol. 53, no. 1, pp. 154–163, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Scherfler and M. Nocker, “Dopamine transporter SPECT: how to remove subjectivity?” Movement Disorders, vol. 24, no. 2, pp. S721–S724, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. H. T. Benamer, J. Patterson, D. J. Wyper, D. M. Hadley, G. J. Macphee, and D. G. Grosset, “Correlation of Parkinsons disease severity and duration with 123I-FP-CIT SPECT striatal uptake,” Movement Disorders, vol. 15, no. 4, pp. 692–698, 2000. View at Google Scholar
  10. K. Badiavas, E. Molyvda, I. Iakovou, M. Tsolaki, K. Psarrakos, and N. Karatzas, “SPECT imaging evaluation in movement disorders: far beyond visual assessment,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 38, no. 4, pp. 764–773, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. R. J. Morton, M. J. Guy, R. Clauss, P. J. Hinton, C. A. Marshall, and E. A. Clarke, “Comparison of different methods of DatSCAN quantification,” Nuclear Medicine Communications, vol. 26, no. 12, pp. 1139–1146, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. I. G. Zubal, M. Early, O. Yuan, D. Jennings, K. Marek, and J. P. Seibyl, “Optimized, automated striatal uptake analysis applied to SPECT brain scans of Parkinson's disease patients,” Journal of Nuclear Medicine, vol. 48, no. 6, pp. 857–864, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Mirzaei, R. Zakavi, M. Rodrigues et al., “Fully automated 3D basal ganglia activity measurement in dopamine transporter scintigraphy (Spectalyzer),” Annals of Nuclear Medicine, vol. 24, no. 4, pp. 295–300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. P. S. Jensen, M. Ziebell, G. Skouboe et al., “Validation of a method for accurate and highly reproducible quantification of brain dopamine transporter SPECT studies,” Journal of Nuclear Medicine Technology, vol. 39, no. 4, pp. 271–278, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. W.-S. Huang, M.-S. Lee, J.-C. Lin et al., “Usefulness of brain 99mTc-TRODAT-1 SPET for the evaluation of Parkinson's disease,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 31, no. 2, pp. 155–161, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. Y.-H. Weng, T.-C. Yen, M.-C. Chen et al., “Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects,” Journal of Nuclear Medicine, vol. 45, no. 3, pp. 393–401, 2004. View at Google Scholar · View at Scopus
  17. M. K. O'Connor and B. J. Kemp, “Single-photon emission computed tomography/computed tomography: basic instrumentation and innovations,” Seminars in Nuclear Medicine, vol. 36, no. 4, pp. 258–266, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. A. K. Buck, S. Nekolla, S. Ziegler et al., “SPECT/CT,” Journal of Nuclear Medicine, vol. 49, no. 8, pp. 1305–1319, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Liu, F. Dong, Z. Meng, B. Zhang, J. Tan, and Y. Wang, “Evaluation of Tourette's syndrome by 99mTc-TRODAT-1 SPECT/CT imaging,” Annals of Nuclear Medicine, vol. 24, no. 7, pp. 515–521, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. R. B. Innis, V. J. Cunningham, J. Delforge et al., “Consensus nomenclature for in vivo imaging of reversibly binding radioligands,” Journal of Cerebral Blood Flow & Metabolism, vol. 27, no. 9, pp. 1533–1539, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. American Association of Physicists (AAPM), “The measurement, reporting, and management of radiation dose in CT. Report of AAPM Task Group 23 of the diagnostic Imaging Council CT committee,” AAPM Report no. 96, American Association of Physicists (AAPM), 2008, http://www.aapm.org/pubs/reports/rpt_96.pdf. View at Google Scholar
  22. L. I.-K. Lin, “A concordance correlation coefficient to evaluate reproducibility,” Biometrics, vol. 45, no. 1, pp. 255–268, 1989. View at Publisher · View at Google Scholar · View at Scopus
  23. J. M. Bland and D. G. Altman, “Statistical methods for assessing agreement between two methods of clinical measurement,” The Lancet, vol. 1, no. 8476, pp. 307–310, 1986. View at Google Scholar · View at Scopus
  24. G. B. McBride, “A proposal for strength-of-agreement criteria for Lin's concordance correlation coefficient,” NIWA Client Report HAM2005-062, 2005, http://www.medcalc.org/download/pdf/McBride2005.pdf. View at Google Scholar
  25. G. Mariani, L. Bruselli, T. Kuwert et al., “A review on the clinical uses of SPECT/CT,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 10, pp. 1959–1985, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Sharma, S. Sharma, S. Ballal, C. Bal, A. Malhotra, and R. Kumar, “SPECT-CT in routine clinical practice: Increase in patient radiation dose compared with SPECT alone,” Nuclear Medicine Communications, vol. 33, no. 9, pp. 926–932, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. P. D. Mozley, J. B. Stubbs, K. Plössl et al., “Biodistribution and dosimetry of TRODAT-1: a technetium-99m tropane for imaging dopamine transporters,” Journal of Nuclear Medicine, vol. 39, no. 12, pp. 2069–2076, 1998. View at Google Scholar · View at Scopus
  28. J. M. Warwick, S. Rubow, M. du Toit, E. Beetge, P. Carey, and P. Dupont, “The role of CT-based attenuation correction and collimator blurring correction in striatal spect quantification,” International Journal of Molecular Imaging, vol. 2011, Article ID 195037, 9 pages, 2011. View at Publisher · View at Google Scholar
  29. A. Paschali, V. Lakiotis, L. Messinis et al., “Dopamine transporter SPECT/CT and perfusion brain SPECT imaging in idiopathic basal ganglia calcinosis,” Clinical Nuclear Medicine, vol. 34, no. 7, pp. 421–423, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. Y.-L. Chiu, C. Hu, J.-Y. Li, M.-J. Weng, W.-C. Lin, and N.-J. Peng, “An incidental finding of cerebral meningioma on 99mTc-TRODAT-1 dopamine transporter SPECT/CT,” Clinical Nuclear Medicine, vol. 37, no. 9, pp. 899–900, 2012. View at Publisher · View at Google Scholar · View at Scopus